<DOC>
	<DOCNO>NCT02640508</DOCNO>
	<brief_summary>The overall purpose study determine overall response rate , efficacy safety combination eribulin Lenvatinib .</brief_summary>
	<brief_title>Eribulin Lenvatinib Advanced Solid Tumors</brief_title>
	<detailed_description>This phase II clinical trial combination eribulin , Lenvatinib . A cycle define 21 day . Eribulin give day 1 8 cycle . Lenvatinib give daily cycle .</detailed_description>
	<mesh_term>Lenvatinib</mesh_term>
	<criteria>Stage IV breast cancer , stage IV NSCLC ( NonSmall Cell Lung Cancer ) ( , stage IV sarcoma ECOG ( Eastern Cooperative Oncology Group ) PS ( Performance Status ) 02 Measurable disease No 4 prior chemotherapeutic regimen metastatic disease Patients must &gt; /= 18 year . Patients may receive eribulin lenvatinib previously Patients must life expectancy great 12 week . Patients may prior diagnosis cancer &gt; 5 year since last treatment consider free disease . Patients must normal organ marrow function define : Leukocytes ≥ 3,000/uL Absolute neutrophil count ≥ 1,500/uL Platelets ≥ 100,000/uL Child Pugh score ≤ 10 Patients must able swallow retain oral medication . All patient must give sign , informed consent prior registration study . Women pregnant lactate eligible study treatment . Patients undergo concomitant radiotherapy NOT eligible participation . Patients receive investigational agent concurrent anticancer therapy NOT eligible participation . Previous systemic treatment and/or radiation therapy allow 14 day washout period prior registration . Lesions radiate previously consider target lesion Prior treatment related side effect must resolve &lt; Grade 2 severity per Common Terminology Criteria Adverse Events ( CTCAE version 4.03 ) , except alopecia infertility . Patients take herbal ( alternative ) medicine NOT eligible participation . Patients must medications time registration . Patients know brain metastasis NOT eligible participation unless brain metastasis treat ( either surgical excision , stereotactic radiosurgery radiotherapy ) stable least 4 wks per MR perform , patient asymptomatic discontinue corticosteroid take purpose . Patients follow condition complication NOT eligible participation : 1 . GI tract disease result inability take oral medication 2 . Malabsorption syndrome 3 . Require IV alimentation 4 . History prior surgical procedure affect absorption 5 . Uncontrolled inflammatory GI disease ( e.g. , Crohn 's , ulcerative colitis ) . 6 . Hypersensitivity component eribulin lenvatinib 7 . History significant neurological ( neuropathy grade 2 ) psychiatric disorder 8 . Significant non neoplastic liver disease ( Cirrhosis , active chronic hepatitis ) 9 . Immunocompromised subject , include patient human immunodeficiency virus 10 . Significant non neoplastic renal disease 11 . Active infection require systemic therapy . 12 . Significant cardiovascular impairment : history congestive heart failure great New York Heart Association ( NYHA ) Class II , uncontrolled arterial hypertension , unstable angina , myocardial infarction stroke within 6 month first dose study drug ; cardiac arrhythmia require medical treatment 13 . Prolongation QTc interval 480 millisecond electrolyte balance normal 14 . Major surgery within 4 week prior first dose study drug .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2016</verification_date>
</DOC>